DMAC
DiaMedica Therapeutics Inc. NASDAQ Listed Aug 3, 2012$6.52
After hrs
$6.52
+0.00%
Mkt Cap $351.3M
52w Low $3.48
43.8% of range
52w High $10.42
50d MA $6.91
200d MA $7.06
P/E (TTM)
-8.8x
EV/EBITDA
-10.4x
P/B
5.2x
Debt/Equity
0.0x
ROE
-58.4%
P/FCF
-12.9x
RSI (14)
—
ATR (14)
—
Beta
1.15
50d MA
$6.91
200d MA
$7.06
Avg Volume
197.3K
About
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials …
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 30, 2026 | AMC | -0.17 | -0.17 | +0.0% | 6.64 | +7.5% | +2.0% | -3.3% | -2.4% | -0.3% | -1.4% | — |
| Nov 12, 2025 | AMC | -0.15 | -0.17 | -13.3% | 6.31 | -6.3% | -14.1% | -6.0% | +1.6% | +9.4% | +15.7% | — |
| Aug 12, 2025 | AMC | -0.18 | -0.18 | +0.0% | 5.22 | -6.1% | +14.9% | +15.1% | +15.5% | +10.3% | +10.5% | — |
| May 13, 2025 | AMC | -0.18 | -0.18 | +0.0% | 3.98 | -1.8% | +0.5% | +2.3% | +5.5% | +7.3% | +4.0% | — |
| Mar 17, 2025 | AMC | -0.17 | -0.18 | -5.9% | 5.99 | +0.2% | -13.0% | -12.5% | -14.2% | -16.9% | -17.4% | — |
| Nov 13, 2024 | AMC | -0.15 | -0.15 | +0.0% | 4.26 | +0.7% | -3.3% | -5.9% | -2.6% | -5.2% | -5.6% | — |
| Aug 7, 2024 | AMC | -0.16 | -0.13 | +18.8% | 3.25 | +0.9% | +3.1% | +9.2% | +8.6% | +10.2% | +7.1% | — |
| May 8, 2024 | AMC | -0.16 | -0.14 | +12.5% | 3.47 | -2.9% | -6.3% | -10.1% | -8.1% | -13.0% | -13.3% | — |
| Mar 19, 2024 | AMC | -0.14 | -0.14 | +0.0% | 2.82 | +1.4% | -1.8% | -4.6% | -2.5% | -5.0% | -3.5% | — |
| Nov 13, 2023 | AMC | -0.14 | -0.12 | +14.3% | 2.34 | -9.4% | +6.8% | +4.7% | +1.7% | +6.4% | +3.4% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Aug 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.01 | $6.02 | +0.2% | +0.3% | -4.2% | -4.0% | -0.2% | -1.3% |
| Jul 18 | Craig-Hallum | Maintains | Buy → Buy | — | $3.93 | $4.04 | +2.8% | +6.4% | +15.5% | +17.0% | +31.0% | +24.2% |
| Jul 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $3.93 | $4.04 | +2.8% | +6.4% | +15.5% | +17.0% | +31.0% | +24.2% |
| Jul 18 | Lake Street | Maintains | Buy → Buy | — | $3.93 | $4.04 | +2.8% | +6.4% | +15.5% | +17.0% | +31.0% | +24.2% |
| May 29 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.16 | $4.24 | +1.9% | +0.7% | -1.2% | +0.2% | -1.0% | +1.0% |
| Mar 19 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.21 | $5.25 | +0.8% | +0.6% | -1.3% | -4.4% | -5.0% | -12.3% |
| Nov 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.12 | $4.16 | +1.0% | -2.7% | +0.7% | -1.9% | -2.4% | +1.5% |
| Oct 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $4.50 | $4.50 | +0.0% | -1.8% | -5.6% | -0.9% | -1.1% | -2.2% |
| Aug 16 | Oppenheimer | Maintains | Outperform → Outperform | — | $3.51 | $3.46 | -1.4% | +2.6% | +1.7% | +5.4% | +5.4% | +13.4% |
| Mar 21 | Craig-Hallum | Maintains | Buy → Buy | — | $2.77 | $2.80 | +1.1% | -2.9% | -0.7% | -3.2% | -1.8% | -4.3% |
Recent Filings
Data updated apr 25, 2026 5:26am
· Source: massive.com